CN112618614B - 一种具有抗抑郁症的刺梨活性提取物及应用 - Google Patents
一种具有抗抑郁症的刺梨活性提取物及应用 Download PDFInfo
- Publication number
- CN112618614B CN112618614B CN202110025958.6A CN202110025958A CN112618614B CN 112618614 B CN112618614 B CN 112618614B CN 202110025958 A CN202110025958 A CN 202110025958A CN 112618614 B CN112618614 B CN 112618614B
- Authority
- CN
- China
- Prior art keywords
- extract
- acid
- total
- rosa roxburghii
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000002547 Rosa roxburghii Species 0.000 title claims abstract description 56
- 235000000640 Rosa roxburghii Nutrition 0.000 title claims abstract description 56
- 230000000694 effects Effects 0.000 title claims abstract description 23
- 150000003648 triterpenes Chemical class 0.000 claims abstract description 35
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 30
- 229930003944 flavone Natural products 0.000 claims abstract description 30
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 30
- 235000011949 flavones Nutrition 0.000 claims abstract description 30
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 17
- 238000001914 filtration Methods 0.000 claims abstract description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000005406 washing Methods 0.000 claims abstract description 15
- 239000002244 precipitate Substances 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000011161 development Methods 0.000 claims abstract description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000003208 petroleum Substances 0.000 claims abstract description 8
- 239000012528 membrane Substances 0.000 claims abstract description 7
- 238000010992 reflux Methods 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 36
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 claims description 32
- 239000002253 acid Substances 0.000 claims description 29
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 18
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 18
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 18
- 235000005875 quercetin Nutrition 0.000 claims description 18
- 229960001285 quercetin Drugs 0.000 claims description 18
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 16
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 16
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 16
- 235000005487 catechin Nutrition 0.000 claims description 16
- 229950001002 cianidanol Drugs 0.000 claims description 16
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 claims description 16
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 16
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 16
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 16
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 16
- 235000005493 rutin Nutrition 0.000 claims description 16
- 229960004555 rutoside Drugs 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 13
- 239000013558 reference substance Substances 0.000 claims description 10
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 229930003935 flavonoid Natural products 0.000 claims description 6
- 150000002215 flavonoids Chemical class 0.000 claims description 6
- 235000017173 flavonoids Nutrition 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- HQZKQSIAHGHXDL-SGOBLLPSSA-N (1r,2r,4as,6ar,6as,6br,8ar,10r,12ar,14bs)-1,10-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-11-oxo-3,4,5,6,6a,7,8,8a,10,12,13,14b-dodecahydro-2h-picene-4a-carboxylic acid Chemical compound C1C(=O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@](O)(C)[C@H]5C4=CC[C@@H]3[C@]21C HQZKQSIAHGHXDL-SGOBLLPSSA-N 0.000 claims description 5
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 5
- HQZKQSIAHGHXDL-UHFFFAOYSA-N 2-oxo-pomolic acid Natural products C1C(=O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(O)(C)C5C4=CCC3C21C HQZKQSIAHGHXDL-UHFFFAOYSA-N 0.000 claims description 5
- ZDGWGNDTQZGISB-UHFFFAOYSA-N acetic acid;perchloric acid Chemical compound CC(O)=O.OCl(=O)(=O)=O ZDGWGNDTQZGISB-UHFFFAOYSA-N 0.000 claims description 5
- 238000004737 colorimetric analysis Methods 0.000 claims description 5
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 5
- 229940096998 ursolic acid Drugs 0.000 claims description 5
- 239000012510 hollow fiber Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241000220317 Rosa Species 0.000 abstract description 30
- 238000000605 extraction Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 238000000926 separation method Methods 0.000 abstract description 3
- 238000001035 drying Methods 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 239000004519 grease Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 22
- 235000013399 edible fruits Nutrition 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 239000000725 suspension Substances 0.000 description 10
- 235000011449 Rosa Nutrition 0.000 description 9
- 229930182470 glycoside Natural products 0.000 description 9
- 150000002338 glycosides Chemical class 0.000 description 9
- 210000004295 hippocampal neuron Anatomy 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 210000001320 hippocampus Anatomy 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 6
- 239000000935 antidepressant agent Substances 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000220324 Pyrus Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 235000014443 Pyrus communis Nutrition 0.000 description 2
- 235000016998 Ribes burejense Nutrition 0.000 description 2
- 241000735566 Ribes burejense Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 238000012346 open field test Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001671 psychotherapy Methods 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000001879 hippocampal ca1 region Anatomy 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000004725 rapid separation liquid chromatography Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000013285 stress animal model Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种具有抗抑郁症的刺梨活性提取物及应用。该活性提取物是通过刺梨果或刺梨果渣采用化学提取或膜分离技术得到,其中所述的化学提取是将鲜榨刺梨果渣或刺梨果经酒精回流提取、过滤、浓缩去乙醇,加水分散水不溶沉淀并过滤,依次用水和石油醚或正己烷洗涤沉淀,去除水溶性物质和油脂,干燥得到。该活性提取物含三萜、黄酮成分,研究发现抗抑郁活性显著,能够用于制备抗抑郁症的药物、辅助药物,具有较高的应用价值和市场前景。本发明既对刺梨产业高值化利用、可持续发展具有重要意义,又为抗抑郁症的药品提供了中间体原料,制备方法简单易行,成本低,可产业化生产。
Description
技术领域
本发明涉及刺梨果或刺梨果渣的提取物,特别是一种具有抗抑郁症的刺梨活性提取物及应用。
背景技术
抑郁症是一种精神紊乱性疾病,在临床上表现为慢性、反复性发作,主要症状为情绪低落、食欲不振和心境功能障碍等消极表现。抑郁症还具有发病率高、致残率高、自杀率高等特点,严重影响患者的身心健康和生活质量,甚至可危及生命。抑郁症患者的主要表现为:心情沉重,对工作与生活丧失基本兴趣,精神疲乏不堪,对生活中的事情总感到力不从心。抑郁症患者的生活态度极度悲观,时常感到非常绝望,且有很强烈的自杀倾向,随着生活节奏的加快、激烈的竞争,加上噪音污染、环境污染及人际关系复杂等,使人们长期处于紧张、焦虑、和不安等状态,导致抑郁症的发病率正逐年飙升,这将严重影响社会公共秩序、降低现代社会人们的生活质量。因此,对抑郁症的治疗成为人们广泛关注的重要问题,得到全球医药工作者的普遍重视。
抑郁症的发病机制和原因都没有明确的说法。于是就有了许多关于抑郁症病因的假说,主要包括以下三个:遗传因素、生化因素及心理-社会因素假说。其中,第一个观点认为:与抑郁症患者的血缘关系越近,则患抑郁症的风险也就越高。而第二个观点则认为,随着多巴胺(DA)、去甲肾上腺素(NE)及5-羟色胺(5-HT)等神经递质浓度的改变,就会引发抑郁症。而最后一个观点则这样认为:如果人们长期保持一种不愉快的情绪,那发生抑郁症的几率就会升高。
临床上对抑郁症患者的治疗方法主要包括心理治疗和药物治疗。心理疗法主要是指通过医生对病患进行正确积极的疏导,使抑郁症患者渐渐摒弃自身的负面、消极情绪,进而对周围世界产生正面、积极的看法,达到改善抑郁症患者精神状态的目的。药物治疗主要包括中药治疗及西药治疗。中药治疗主要依据抑郁症患者常见的肝气郁结等现象,利用中药药物为其疏肝理气,从而缓解抑郁症的症状,达到治疗的效果。西药治疗是当下最主要的抑郁症治疗方法。
目前社会上常见的西药药物有三环类抗抑郁药,如丙咪嗪、阿米替林等;选择性5-羟色胺重摄取抑制剂,如氟西汀、帕罗西汀、舍曲林等;5-羟色胺/去甲肾上腺素重摄取双重抑制剂,如万拉法新、度洛西汀等。但这些药物均存在起效慢、疗效低、毒副作用大等弊端。因此,从天然产物或者药食用植物资源中挖掘新型的抗抑郁药物,寻找和开发起效迅速、副作用小的的抗抑郁新药已经刻不容缓。
刺梨(Rosa roxbughii Tratt)为蔷薇科落叶灌木植物。刺梨果被誉“维 C 之王”、“中国登义果”以及“炎黄圣果”,是第三代水果(3G)代表的珍贵水果资源。刺梨已被列入卫健委批准的食品新资源名单品种,现为普通食品;1994 和 2003 版《贵州省中药材、民族药材质量标准》均将刺梨收录其中,刺梨具有药用和食用的双重属性。目前刺梨的药理作用主要包括以下几个方面:抗氧化、延缓衰老、调节机体免疫功能、抗肿瘤、降血糖、解毒镇静、解酒护肝、治疗口腔溃疡、治疗胃溃疡及促消化、抗动脉粥样硬化、抗肾纤维化及辐射防护等,但是目前还没有关于刺梨具有抗抑郁活性的研究。
发明内容
本发明的目的在于,从刺梨果或刺梨果渣中利用化学分离或者膜分离技术提取出一种具有抗抑郁症的刺梨活性提取物及并将其应用到抗抑郁的药物中。为刺梨产业的高值化、可持续发展利用提供新的途径,为实现上述目的,所采取的技术方案为:一种具有抗抑郁症的刺梨活性提取物,所述提取物含有总三萜和总黄酮,其中总三萜的含量为30%-45%;总黄酮的含量为1%~3%。
上述总三萜包括蔷薇酸、2-氧代坡模醇酸、刺梨苷 F1和刺梨酸;所述总黄酮包括槲皮素、儿茶素、二氢杨梅素和芦丁。
上述总三萜的含量为蔷薇酸、2-氧代坡模醇酸、刺梨苷F1和刺梨酸的含量总和,总黄酮的含量为槲皮素、儿茶素、二氢杨梅素和芦丁的含量总和。
上述总三萜的含量是以熊果酸为对照品,利用香草醛-冰醋酸-高氯酸显色比色法测定得到;所述总黄酮的含量是以槲皮素、儿茶素、二氢杨梅素和芦丁为对照品,利用高效液相色谱法测定得到。
上述的提取物的制备方法包括以下步骤:取刺梨果或刺梨果渣,用重量为刺梨果或刺梨果渣重量的5-10倍的50-95%乙醇水溶液回流提取2-4次,每次1-2小时,过滤,合并滤液,回收乙醇,在滤液中加体积为滤液体积的0.5-1倍的水进行分散,抽滤,水洗沉淀2-4次,然后用石油醚或正己烷洗沉淀2-4次,冷冻干燥或真空减压干燥沉淀得提取物。
上述的提取物的另一种制备方法包括以下步骤:取刺梨果或刺梨果渣,用重量为刺梨果或刺梨果渣重量的5-10倍的50-95%乙醇水溶液回流提取2-4次,每次1-2小时,过滤,合并滤液,回收乙醇,采用0.45μm中空纤维膜过滤,水洗沉淀2-4次,然后用石油醚或正己烷洗沉淀2-4次,冷冻干燥或真空减压干燥沉淀得提取物。
上述提取物具有抗抑郁活性,可用于制备抗抑郁症的药物、药物中间体。
上述提取物制备药物,直接使用或者以组合物的形式使用;所述组合物包括0.1–99%的提取物,其余为载体;所述药物的剂型为硬胶囊、片剂、口服液、颗粒剂、软胶囊或滴丸剂。
其中,刺梨活性提取物鉴定方法为:向提取物样品中加入1mL 70%的甲醇内标提取液,斡旋5 min混匀,离心(1200 r/min, 4℃)10min,取上清液用微孔滤膜(0.22µm)过滤,保存于进样瓶中,用于LC-MS/MS检测,图1为提取物的LC-MS离子流图。
色谱质谱采集条件:使用Thermo Fisher Scientific公司生产的DionexUltimate 3000 RSLC (HPG)液相色谱仪与Thermo Scientific Q Exactive Focus质谱仪进行检测,HESI-II离子源,Thermo Fisher Hypersil GOLD a Q (100*2.1 mm, 1.9μm)色谱柱。离子源参数设置为Spray Voltage(3.0kV(+)/2.5kV (-));Capillary Temperature(320℃);Sheath Gas(35 arb);AUX Gas(10 arb);Sweep Gas(0 arb);Probe HeaterTemperature(350℃);S-Lens(60)。流动相中A相为乙腈(0.1%甲酸)、B相为0.1%甲酸水,梯度洗脱0~50min A为5%~95%,流速为0.3 mL/min,柱温为40℃。质谱扫描参数设置Scan mode(Full MS-ddms2),Full MS scan range(100 to 1500m/z),Spectrum data type(Profile),Resolution(Full MS: 70,000,MS/MS: 17,500),AGC target(Full MS:1e6,MS/MS:2e5),Maximum IT(Full MS: 100 ms,MS/MS: 50 ms),Isolation width(1.5m/z),Dynamic exclution (5 s),NCE (Stepped NCE):20, 40, 60。对得到的提取物进行质谱分析,如图2-6所示。图2-6分别为刺梨果渣活性提取物中槲皮素、刺梨酸、蔷薇酸、2-氧代坡模醇酸、刺梨苷 F1的质谱图。
与现有技术相比,本发明提供的提取物是从刺梨果或者刺梨果渣中提取富集制备而成,并对提取物中总三萜和总黄酮做了定性分析,确定了对急性酒精性肝损伤具有辅助保护作用的具体成分为总三萜:蔷薇酸、2-氧代坡模醇酸、刺梨苷 F1和刺梨酸;总黄酮包括槲皮素、儿茶素、二氢杨梅素和芦丁。且每个成分的具体含量不同,体现的活性不同,当总三萜的含量为30%-45%;总黄酮的含量为1%~3%表现出很好的抗抑郁活性。
为了进一步验证本发明所制备的刺梨活性提取物抗抑郁活性,通过动物试验,表明了刺梨活性提取物具有抗抑郁活性,从抑郁症模型小鼠旷场实验总路程统计结果表明与模型组相比,刺梨活性提取物给药组的总路程显著增加(P<0.05);从抑郁症模型小鼠悬尾实验不动时间统计结果表明与模型组比较,刺梨活性提取物给药组在悬尾实验中的不动时间显著降低(P < 0.001);从刺梨活性提取物对抑郁症小鼠糖水偏好的影响实验结果表明刺梨活性提取物能够提高小鼠对蔗糖的偏爱(P<0.01),结果与阿米替林组相似(P<0.01),差异有统计学意义;刺梨活性提取物对抑郁症模型小鼠海马区域的HE染色结果表明刺梨活性提取物各剂量给药组小鼠海马CA1区域病理损伤较模型组明显减轻;从刺梨活性提取物对抑郁症模型小鼠海马神经元的形态学改变实验结果表明刺梨活性提取物各剂量给药组小鼠海马神经元排列尚整齐,凋亡神经元细胞数较少,说明刺梨活性提取物对海马神经元具有保护作用。以上各组实验结果揭示了刺梨活性提取物抗抑郁活性效果显著。
附图说明
图1刺梨活性提取物LC-MS离子流图;
图2为刺梨活性提取物中槲皮素的质谱图;
图3为刺梨活性提取物中刺梨酸的质谱图;
图4为刺梨活性提取物中蔷薇酸的质谱图;
图5为刺梨活性提取物中2-氧代坡模醇酸的质谱图;
图6为刺梨活性提取物中刺梨苷 F1的质谱图;
图7刺梨活性提取物对抑郁症模型小鼠旷场实验总路程图;
图8刺梨活性提取物对抑郁症模型小鼠悬尾不动时间统计柱形图;
图9刺梨活性提取物对抑郁症模型小鼠海马区域HE染色结果图;
图10刺梨活性提取物对抑郁症模型小鼠海马神经元的形态学图。
具体实施方式
实施例1
一种具有抗抑郁症的刺梨活性提取物,所述提取物含有总三萜和总黄酮,其中总三萜的含量为30%;总黄酮的含量为3%。
所述的刺梨活性提取物中总三萜包括蔷薇酸、2-氧代坡模醇酸、刺梨苷 F1和刺梨酸;所述总黄酮包括槲皮素、儿茶素、二氢杨梅素和芦丁。
其中所述总三萜的含量为蔷薇酸、2-氧代坡模醇酸、刺梨苷 F1和刺梨酸的含量总和,总黄酮的含量为槲皮素、儿茶素、二氢杨梅素和芦丁的含量总和。
上述总三萜的含量是以熊果酸为对照品,利用香草醛-冰醋酸-高氯酸显色比色法测定得到;所述总黄酮的含量是以槲皮素、儿茶素、二氢杨梅素和芦丁为对照品,利用高效液相色谱法测定得到。
上述的提取物的制备方法包括以下步骤:取刺梨果或刺梨果渣,用重量为刺梨果或刺梨果渣重量的5倍的95%乙醇水溶液回流提取2次,每次2小时,过滤,合并滤液,回收乙醇,在滤液中加体积为滤液体积的0.5倍的水进行分散,抽滤,水洗沉淀4次,然后用石油醚或正己烷洗沉淀2次,冷冻干燥或真空减压干燥沉淀得提取物。
实施例2
一种具有抗抑郁症的刺梨活性提取物,所述提取物含有总三萜和总黄酮,其中总三萜的含量为45%;总黄酮的含量为1%。
所述的刺梨活性提取物中总三萜包括蔷薇酸、2-氧代坡模醇酸、刺梨苷 F1和刺梨酸;所述总黄酮包括槲皮素、儿茶素、二氢杨梅素和芦丁。
其中所述总三萜的含量为蔷薇酸、2-氧代坡模醇酸、刺梨苷 F1和刺梨酸的含量总和,总黄酮的含量为槲皮素、儿茶素、二氢杨梅素和芦丁的含量总和。
上述总三萜的含量是以熊果酸为对照品,利用香草醛-冰醋酸-高氯酸显色比色法测定得到;所述总黄酮的含量是以槲皮素、儿茶素、二氢杨梅素和芦丁为对照品,利用高效液相色谱法测定得到。
上述的提取物的另一种制备方法包括以下步骤:取刺梨果或刺梨果渣,用重量为刺梨果或刺梨果渣重量的10倍的50%乙醇水溶液回流提取2次,每次1小时,过滤,合并滤液,回收乙醇,采用0.45μm中空纤维膜过滤,水洗沉淀4次,然后用石油醚或正己烷洗沉淀2次,冷冻干燥或真空减压干燥沉淀得提取物。
实施例3
一种具有抗抑郁症的刺梨活性提取物,所述提取物含有总三萜和总黄酮,其中总三萜的含量为40%;总黄酮的含量为2%。
所述的刺梨活性提取物中总三萜包括蔷薇酸、2-氧代坡模醇酸、刺梨苷 F1和刺梨酸;所述总黄酮包括槲皮素、儿茶素、二氢杨梅素和芦丁。
其中所述总三萜的含量为蔷薇酸、2-氧代坡模醇酸、刺梨苷 F1和刺梨酸的含量总和,总黄酮的含量为槲皮素、儿茶素、二氢杨梅素和芦丁的含量总和。
上述总三萜的含量是以熊果酸为对照品,利用香草醛-冰醋酸-高氯酸显色比色法测定得到;所述总黄酮的含量是以槲皮素、儿茶素、二氢杨梅素和芦丁为对照品,利用高效液相色谱法测定得到。
上述的提取物的另一种制备方法包括以下步骤:取刺梨果或刺梨果渣,用重量为刺梨果或刺梨果渣重量的8倍的75%乙醇水溶液回流提取3次,每次1.5小时,过滤,合并滤液,回收乙醇,采用0.45μm中空纤维膜过滤,水洗沉淀3次,然后用石油醚或正己烷洗沉淀3次,冷冻干燥或真空减压干燥沉淀得提取物。
实施例4
本发明提取物的应用,将提取物制备成抗抑郁症的口服液。一种具有抗抑郁症的刺梨活性提取物,所述提取物含有总三萜和总黄酮,其中总三萜的含量为30%;总黄酮的含量为3%。取100 mg的活性提取物溶解于1000mL纯水中,过滤(0.45μm),滤液在无菌条件下装入30mL口服液瓶中。
实施例5
本发明提取物的应用,将提取物制备成抗抑郁症的含片。一种具有抗抑郁症的刺梨活性提取物,所述提取物含有总三萜和总黄酮,其中总三萜的含量为40%;总黄酮的含量为2%。按照重量为刺梨活性提取物50mg/片计,按照片剂的常规方法制备。
以上所述,仅是本发明的较佳实施例而已,并非对本发明作任何形式上的限制,任何未脱离本发明技术方案内容,依据本发明的技术实质对以上实施例所作的任何简单修改、变换材质、等同变化与修饰,均仍属于本发明技术方案的范围内。
为了进一步验证本发明刺梨活性提取物抗抑郁活性,选用实施例1制备的刺梨活性提取物(总三萜的含量为30%;总黄酮的含量为3%)开展药理实验,实验方法与结果如下。
1.试剂与仪器
1.1试剂和供试样品
尼氏染色液(G1434)、HE染色液(G1120)、柠檬酸盐缓冲液、PBS购买于索莱宝生物科技有限公司。供试样品:刺梨果渣活性提取物(总三萜30%,总黄酮2.3%)。
1.2 仪器
LeicaTP1020自动阻止脱水机:Leica包埋机:LeicaCM2245轮转式石蜡切片机:光学显微镜:德国Leica公司产品;电热鼓风干燥机:上海博讯实业公司;光学显微镜:德国Leica公司;悬尾实验视频分析系统(ZH-XWT)、强迫游泳实验箱(ZH)、旷场实验箱(ZH-OFT)购买于安徽正华生物仪器设备有限公司。
2.试验方法
2.1主要实验用液的配制
2.1.1主要溶液的配制
1)PBS液:称取KCl 0.20 g,NaCl 8.0 g,KH2PO4 0.20 g,Na2HPO4·12H2O 3.48 g,加双蒸水定容至1L。
2)4%甲醛溶液:将40%甲醛溶液用PBS液稀释至4%,调pH值为7.4左右。
3)柠檬酸盐缓冲液:购买的1包柠檬酸盐缓冲液用双蒸水定容至2L。
2.2 实验分组及给药
1) 模型与制备
所有小鼠自由饮水与进食,在光暗周期为12h的安静环境适应性饲养一周后,采用Willner P方法改良为慢性轻度不可预见应激动物模型(CUMS)结合孤养进行实验。接受应激处理的小鼠在21天内随机接受不同刺激,每日1种,同种刺激不能连续出现。应激的应激操作方法如下:倾斜鼠笼(45°,24h),禁水、禁食(24h),冰水游泳(4℃,5min),夹尾(1min),热应激(45℃,5min),闪光刺激(频率 3次/分),潮湿垫料(24h),昼夜颠倒(24h)。
2) 分组及给药
实验前2天每只鼠进行1h糖水偏爱度实验,根据糖水偏爱度的结果选取无显著差异的小鼠分别称取体重。实验前1天进行开场实验,剔除中央活动总路程结果差异较大的小鼠,随机将60只小鼠随机分为空白对照组;模型组;阿米替林组(15mg/kg);梨果渣活性提取物低、中、高(50mg/kg、100mg/kg和200mg/kg)口服给药组,每组10只。造模结束后,正常组和模型组灌胃等体积蒸馏水,阿米替林组和梨果渣活性提取物低、中、高各剂量给药组连续给药21天。
2.3行为学检测及及标本制备
给药结束后做小鼠强迫游泳、旷场实验及悬尾实验。行为学实验结束后第二天每组随机抽取3只小鼠脱臼处死,开胸暴露心脏,经0.1M PBS液及预冷的4%多聚甲醛(0.1MPBS配置)透心灌注后取脑,放入4%多聚甲醛溶液中固定一周,石蜡包埋后5μm连续切片,做常规HE染色和尼氏染色。剩余小鼠脱臼处死取小鼠海马及前额叶组织放入EP管中,﹣80℃低温保存备用。
3 数据处理
4 试验结果
4.1刺梨果渣活性提取物对抑郁症模型小鼠旷场实验总路程(mm)统计结果
如图7所示,与空白组相比,模型组小鼠在旷场实验中总路程降低(P<0.05);与模型组相比,刺梨果渣活性提取物给药组的总路程显著增加(P<0.05)。
4.2刺梨果渣活性提取物对抑郁症模型小鼠悬尾实验不动时间统计结果
图8为刺梨果渣活性提取物对抑郁症小鼠悬尾实验不动实验统计结果,如图8所示,空白组比较,模型组小鼠悬尾实验的不动时间都有显著增加(P < 0.001);与模型组比较,刺梨果渣活性提取物给药组在悬尾实验中的不动时间显著降低(P < 0.001)。
4.3刺梨果渣活性提取物对抑郁症小鼠糖水偏好的影响
如表2显示,与空白对照组比较,模型组小鼠的蔗糖偏好明显降低(P<0.01),差异有统计学意义;与模型组小鼠相比,刺梨果渣活性提取物能够提高小鼠对蔗糖的偏爱(P<0.01),结果与阿米替林组相似(P<0.01),差异有统计学意义。
组别 | 剂量(mg/kg) | 糖水偏好分数 |
空白组 | 0.720土0.08<sup>**</sup> | |
模型组 | 0.506土0.09 | |
阿米替林组 | 15 | 0.858土0.11<sup>**</sup> |
活性提取物低剂量组 | 50 | 0.882土0.05<sup>**</sup> |
活性提取物中剂量组 | 100 | 0.896土0.06<sup>**</sup> |
活性提取物高剂量 | 200 | 0.886土0.04<sup>**</sup> |
注:与模型组相比,P **<0.01。
4.4刺梨果渣活性提取物对抑郁症模型小鼠海马区域的HE染色结果
如图9所示,HE染色结果显示,在光学显微镜下发现空白对照组小鼠海马CA1区域神经元数量多且排列整齐,基质丰富,细胞保持有原有的生长形态,细胞核完整,染色均匀;而模型组海马CA1区域神经元细胞减少且排列疏松,细胞间隙增大,细胞核固缩,被染成深蓝色,存在大量细胞凋亡;阳性药组及刺梨果渣活性提取物各剂量给药组小鼠海马CA1区域病理损伤较模型组明显减轻。
4.5刺梨果渣活性提取物对抑郁症模型小鼠海马神经元的形态学改变
如图10所示,空白组小鼠尼氏染色海马神经元呈颗粒状,排列紧密、整齐,凋亡神经元细胞数较少;模型组小鼠尼氏染色海马神经元分散稀疏、排列散乱、凋亡神经元细胞数较多,存活细胞数显著减少;阳性药及刺梨果渣活性提取物各剂量给药组小鼠海马神经元排列尚整齐,凋亡神经元细胞数较少;提示刺梨果渣活性提取物对海马神经元具有保护作用。
Claims (3)
1.一种具有抗抑郁症的刺梨活性提取物,其特征在于:所述提取物含有总三萜和总黄酮,其中总三萜的含量为30%-45%;总黄酮的含量为1%~3%;
其中所述总三萜包括蔷薇酸、2-氧代坡模醇酸、刺梨苷F1和刺梨酸;所述总黄酮包括槲皮素、儿茶素、二氢杨梅素和芦丁;所述总三萜的含量为蔷薇酸、2-氧代坡模醇酸、刺梨苷F1和刺梨酸的含量总和,总黄酮的含量为槲皮素、儿茶素、二氢杨梅素和芦丁的含量总和;所述总三萜的含量是以熊果酸为对照品,利用香草醛-冰醋酸-高氯酸显色比色法测定得到;所述总黄酮的含量是以槲皮素、儿茶素、二氢杨梅素和芦丁为对照品,利用高效液相色谱法测定得到;所述的提取物的制备方法包括以下步骤:取刺梨果,用重量为刺梨果重量的5-10倍的50-95%乙醇水溶液回流提取2-4次,每次1-2小时,过滤,合并滤液,回收乙醇,在滤液中加体积为滤液体积的0.5-1倍的水进行分散,抽滤,水洗沉淀2-4次,然后用石油醚或正己烷洗沉淀2-4次,冷冻干燥或真空减压干燥沉淀得提取物。
2.根据权利要求1所述的提取物的制备方法,其特征在于:取刺梨果,用重量为刺梨果重量的5-10倍的50-95%乙醇水溶液回流提取2-4次,每次1-2小时,过滤,合并滤液,回收乙醇,采用0.45μm中空纤维膜过滤,水洗沉淀2-4次,然后用石油醚或正己烷洗沉淀2-4次,冷冻干燥或真空减压干燥沉淀得提取物。
3.根据权利要求1所述的提取物的应用,其特征在于:所述提取物应用于制备抗抑郁症的药物;直接使用或者以组合物的形式使用;所述组合物包括0.1–99%的提取物,其余为载体;所述药物的剂型为硬胶囊、片剂、口服液、颗粒剂、软胶囊或滴丸剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110025958.6A CN112618614B (zh) | 2021-01-08 | 2021-01-08 | 一种具有抗抑郁症的刺梨活性提取物及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110025958.6A CN112618614B (zh) | 2021-01-08 | 2021-01-08 | 一种具有抗抑郁症的刺梨活性提取物及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112618614A CN112618614A (zh) | 2021-04-09 |
CN112618614B true CN112618614B (zh) | 2022-10-28 |
Family
ID=75293854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110025958.6A Active CN112618614B (zh) | 2021-01-08 | 2021-01-08 | 一种具有抗抑郁症的刺梨活性提取物及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112618614B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113331323A (zh) * | 2021-05-26 | 2021-09-03 | 广州王老吉大健康产业有限公司 | 一种梨与刺梨的组合物及其应用 |
CN114129579B (zh) * | 2021-11-03 | 2023-06-20 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 刺梨苷在制备抗抑郁症药物中的应用 |
CN115720972A (zh) * | 2022-11-18 | 2023-03-03 | 国药集团贵州大健康产业发展有限公司 | 一种强化美白功效的刺梨汁饮品及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102894152A (zh) * | 2012-09-27 | 2013-01-30 | 贵州秀生堂医药生物有限公司 | 一种保健茶及其制备方法 |
CN104605352A (zh) * | 2015-01-23 | 2015-05-13 | 丸永贸易(上海)有限公司 | 用于促进人体血液循环、温补肾阳的玛卡和刺梨营养组合物,其制备方法和用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102145062B (zh) * | 2011-03-29 | 2013-03-20 | 贵州省中国科学院天然产物化学重点实验室 | 刺梨果活性提取物及其制备方法、检测方法和应用 |
CN108926554A (zh) * | 2018-10-12 | 2018-12-04 | 中国科学院昆明植物研究所 | 儿茶素在制备治疗中枢神经系统疾病药物中的应用 |
-
2021
- 2021-01-08 CN CN202110025958.6A patent/CN112618614B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102894152A (zh) * | 2012-09-27 | 2013-01-30 | 贵州秀生堂医药生物有限公司 | 一种保健茶及其制备方法 |
CN104605352A (zh) * | 2015-01-23 | 2015-05-13 | 丸永贸易(上海)有限公司 | 用于促进人体血液循环、温补肾阳的玛卡和刺梨营养组合物,其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN112618614A (zh) | 2021-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112618614B (zh) | 一种具有抗抑郁症的刺梨活性提取物及应用 | |
US6083932A (en) | Pharmaceutical compositions derived from ginseng and methods of treatment using same | |
Gillis | Panax ginseng pharmacology: a nitric oxide link? | |
Dashora et al. | Antitumor activity of Dendrophthoe falcata against ehrlich ascites carcinoma in swiss albino mice | |
CN101219161B (zh) | 香青兰提取物和香青兰滴丸及其生产方法 | |
Alkandahri et al. | Antidiabetic activity of extract and fractions of Castanopsis costata leaves on alloxan-induced diabetic mice | |
TWI300352B (en) | Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract | |
CN105920476B (zh) | 防治阿尔茨海默病中药组合物及其制备方法 | |
CN101863871A (zh) | 蔷薇红景天总苷及其医药用途和制备方法 | |
CN112645808A (zh) | 一种高良姜中分离的5-羟基-1,7-二苯基-3-庚酮及其应用 | |
CN112472729A (zh) | 香青藤在制备用于治疗人胶质瘤的药物中的应用 | |
CN109674866A (zh) | 一种抗胃肠癌药物组合物、制备方法及其应用 | |
CN1969945A (zh) | 补血中药制剂及其生产方法 | |
CN107854522A (zh) | 一种组合物及其制备方法和用途 | |
CN116115717B (zh) | 一种达原液体制剂的含量检测方法 | |
Li et al. | Identification of chemical constituents of Qingjin Yiqi granules and comparative study on pharmacokinetics of 23 main bioactive components in normal and Lung-Qi deficiency rats by UPLC-MS/MS method | |
CN100444849C (zh) | 刺蒺藜提取物的新用途 | |
CN102716272B (zh) | 一种延缓衰老和抗疲劳的中药组合物、其软胶囊及制备方法 | |
Semalty et al. | Herbal drugs in chronic fatigue syndrome: an overview | |
CN107485615A (zh) | 粗壮女贞苷c及其组合物在制备治疗高脂血症及减肥药物中的用途 | |
CN107648565A (zh) | 一种治疗抑郁症的药物组合物及其制备方法 | |
KR101319829B1 (ko) | 생더덕과 찐더덕의 추출물 및 분획물을 포함하는 치매 예방 또는 치료 및 인지능 개선용 약학적 조성물 또는 기능성 식품 조성물 | |
CN112717031A (zh) | 一种用于治疗阿尔茨海默症的药物组合物及其制备方法 | |
CN105193887A (zh) | 一种刺五加提取物及其抗氧化用途 | |
Panjaitan et al. | Liver Organ Impairment Due to the Consumption of Kratom Leaves (Mitragyna speciosa Korth.) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |